Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]
In development [GID-TA10430] Expected publication date: TBC
Search results
608 results
-
-
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1065
In development [GID-TA10385] Expected publication date: TBC
-
Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712]
In development [GID-TA10572] Expected publication date: TBC
-
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]
In development [GID-TA10122] Expected publication date: TBC
-
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]
In development [GID-TA10342] Expected publication date: TBC
-
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
In development [GID-TA10495] Expected publication date: 18 August 2021
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 15 September 2021
-
Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]
In development [GID-TA10417] Expected publication date: 15 September 2021
-
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617
In development [GID-TA10545] Expected publication date: 21 April 2021
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable or metastatic advanced breast cancer after 2 or more anti-HER2 therapies [ID3828]
In development [GID-TA10708] Expected publication date: TBC
-
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
In development [GID-TA10633] Expected publication date: TBC
-
Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]
In development [GID-TA10554] Expected publication date: 20 October 2021
-
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683
In development [GID-TA10537] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Ofatumumab for treating relapsing multiple sclerosis [ID1677]
In development [GID-TA10557] Expected publication date: TBC
-
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]
In development [GID-TA10523] Expected publication date: TBC
-
Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]
In development [GID-TA10759] Expected publication date: TBC
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: TBC
-
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]
In development [GID-TA10391] Expected publication date: TBC
-
Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604
In development [GID-TA10518] Expected publication date: TBC
-
Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]
In development [GID-TA10352] Expected publication date: 13 October 2021
-
Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]
In development [GID-TA10222] Expected publication date: TBC
-
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
In development [GID-TA10656] Expected publication date: 02 March 2022
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: 05 May 2021
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
In development [GID-TA10457] Expected publication date: 19 May 2021
-
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
In development [GID-TA10711] Expected publication date: 15 September 2021
-
Bimekizumab for treating moderate to severe chronic plaque psoriasis [ID2692]
In development [GID-TA10649] Expected publication date: 22 September 2021
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC
-
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
-
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care
In development [GID-DT28] Expected publication date: TBC
-
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis
In development [GID-DT9] Expected publication date: TBC
-
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
In development [GID-DT14] Expected publication date: TBC
-
The Assurance Nasal Alar SpO2 Sensor (discontinued)
In development [GID-MT510] Expected publication date: TBC
-
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
In development [GID-MT517] Expected publication date: TBC
-
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)
In development [GID-MT536] Expected publication date: TBC
-
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)
In development [GID-MT130] Expected publication date: TBC
-
Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)
In development [GID-MT163] Expected publication date: TBC
-
Microthane implants for breast reconstruction or breast augmentation (discontinued)
In development [GID-MT267] Expected publication date: TBC
-
SILK artery reconstruction device (discontinued)
In development [GID-MT81] Expected publication date: TBC
-
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)
In development [GID-MT516] Expected publication date: TBC
-
OraQuick® HCV Rapid Antibody Test (discontinued)
In development [GID-MT117] Expected publication date: TBC
-
Workplace health for employees with disabilities and long-term conditions
In development [GID-PHG58] Expected publication date: TBC
-
Workplace health - older employees
In development [GID-PHG59] Expected publication date: 24 March 2016
-
Personal, social, health and economic education focusing on sex and relationships and alcohol education
In development [GID-PHG0] Expected publication date: TBC
-
Housing: planning to improve health and wellbeing
In development [GID-NG10053] Expected publication date: TBC
-
Assessment, referral and management of Adrenal dysfunction
In development [GID-NG10052] Expected publication date: TBC
-
Diagnostic services
In development [GID-CGWAVE0773] Expected publication date: TBC
-
Reducing the mortality and morbidity for healthcare associated infections
In development [GID-NG10059] Expected publication date: TBC
-
Hernia
In development [GID-CGWAVE0771] Expected publication date: TBC
-
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610
In development [GID-TA10499] Expected publication date: TBC